AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24646819 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Number of subjects: 138
Study 24646819 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 138
Study 24646819 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 138
Study 24646819 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 138
Study 22698597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid regurgitation treatment (group T)
Number of subjects: 167
Study 22698597 — intervention group
Group type: COMPARATOR
Intervention: No tricuspid regurgitation treatment (group no-T)
Number of subjects: 167
Study 22698597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid regurgitation treatment (group T) in subgroup A (TAD/BSA ≤ 21 mm/m2)
Number of subjects: 167
Study 22698597 — intervention group
Group type: COMPARATOR
Intervention: No tricuspid regurgitation treatment (group no-T) in subgroup A (TAD/BSA ≤ 21 mm/m2)
Number of subjects: 167
Study 22698597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid valvoplasty (group T) in subgroup B (TAD/BSA > 21 mm/m2)
Number of subjects: 167
Study 22698597 — intervention group
Group type: COMPARATOR
Intervention: No tricuspid regurgitation treatment (group no-T) in subgroup B (TAD/BSA > 21 mm/m2)
Number of subjects: 167
Study 19543102 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing humorous films
Number of subjects: 24
Study 19543102 — intervention group
Group type: COMPARATOR
Intervention: Viewing control nonhumorous films
Number of subjects: 24
Study 18412823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-family group intervention (Coffee and Families Education and Support)
Number of subjects: 197
Study 18412823 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 197
Study 18412823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-family group intervention
Number of subjects: 197
Study 16162882 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 16162882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12567343 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar block
Number of subjects: 85
Study 12567343 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine 1 mg/kg
Number of subjects: 85
Study 10603722 — intervention group
Group type: EXPERIMENTAL
Intervention: Leprosy patients with facial nerve involvement
Number of subjects: 3
Study 10603722 — intervention group
Group type: EXPERIMENTAL
Intervention: Leprosy patients without facial nerve involvement
Number of subjects: 3
Study 10603722 — intervention group
Group type: COMPARATOR
Intervention: Non‐leprosy controls
Number of subjects: 3
Study 7724097 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 240
Study 7724097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 2325569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocaltrol 0.25 micrograms twice daily
Number of subjects: 0
Study 2325569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6269476 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim and polymyxin B (TP)
Number of subjects: 68
Study 6269476 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim, sulphacetamide and polymyxin B (TSP)
Number of subjects: 68
Study 31023259 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral violence
Number of subjects: 930
Study 31023259 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral victimization
Number of subjects: 930
Study 31023259 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral perpetration
Number of subjects: 930
Study 28971360 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 36
Study 28971360 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 36
Study 25851423 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 59
Study 25851423 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 59
Study 23824103 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage pulsed-dose-rate brachytherapy (PDR-BT)
Number of subjects: 18
Study 22089721 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-normal SBP (<120 mm Hg)
Number of subjects: 20330
Study 22089721 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal SBP (120-<130 mm Hg)
Number of subjects: 20330
Study 22089721 — intervention group
Group type: COMPARATOR
Intervention: High-normal SBP (130-<140 mm Hg)
Number of subjects: 20330
Study 22089721 — intervention group
Group type: EXPERIMENTAL
Intervention: High SBP (140-<150 mm Hg)
Number of subjects: 20330
Study 22089721 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high SBP (≥150 mm Hg)
Number of subjects: 20330
Study 19148936 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 30
Study 19148936 — intervention group
Group type: COMPARATOR
Intervention: No inhaled nitric oxide (no iNO)
Number of subjects: 30
Study 17335364 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) with azithromycin administered orally 3 days before SRP
Number of subjects: 34
Study 17335364 — intervention group
Group type: COMPARATOR
Intervention: Conventional SRP (Control group)
Number of subjects: 34
Study 17335364 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) with azithromycin
Number of subjects: 34
Study 15377354 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 30
Study 15377354 — intervention group
Group type: COMPARATOR
Intervention: Aldara excipient
Number of subjects: 30
Study 11164856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1200 mg/day for 30 days
Number of subjects: 39
Study 11164856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11271904 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carbogen gas mixture
Number of subjects: 14
Study 11271904 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% carbogen gas mixture
Number of subjects: 14
Study 11271904 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% carbogen gas mixture
Number of subjects: 14
Study 11271904 — intervention group
Group type: COMPARATOR
Intervention: Control gas
Number of subjects: 14
Study 9182112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg bid
Number of subjects: 162
Study 9182112 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate 500 mg/125 mg tid
Number of subjects: 162
Study 1514154 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG guided percutaneous CVC placement
Number of subjects: 34
Study 1514154 — intervention group
Group type: COMPARATOR
Intervention: Blind percutaneous CVC placement (Control)
Number of subjects: 34
Study 1514154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ECG guided CVC placement
Number of subjects: 34
Study 6637720 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instruction with uncaptioned videocassette signed by an interpreter
Number of subjects: 0
Study 6637720 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction with captioned videocassette
Number of subjects: 0
Study 6637720 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction through signed instruction
Number of subjects: 0
Study 6637720 — intervention group
Group type: COMPARATOR
Intervention: Standard 4-hour course for non-deaf group
Number of subjects: 0
Study 31507059 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity Score Analysis
Number of subjects: 0
Study 31507059 — intervention group
Group type: COMPARATOR
Intervention: Analysis of Covariance (ANCOVA)
Number of subjects: 0
Study 29393261 — intervention group
Group type: EXPERIMENTAL
Intervention: NEC-surgical
Number of subjects: 133
Study 29393261 — intervention group
Group type: EXPERIMENTAL
Intervention: NEC-medical
Number of subjects: 133
Study 29393261 — intervention group
Group type: COMPARATOR
Intervention: Reference
Number of subjects: 133
Study 26684170 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin 2‐2 genotype
Number of subjects: 486
Study 26684170 — intervention group
Group type: COMPARATOR
Intervention: Haptoglobin 1 genotype
Number of subjects: 486
Study 24933726 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 302
Study 24933726 — intervention group
Group type: COMPARATOR
Intervention: No PTSD
Number of subjects: 302
Study 22617188 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 0
Study 20926948 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day with standard conventional therapy (n=55)
Number of subjects: 110
Study 20926948 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n=55)
Number of subjects: 110
Study 18580172 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction II (LTSII)
Number of subjects: 100
Study 18580172 — intervention group
Group type: COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 100
Study 16083709 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 16 weeks (group A)
Number of subjects: 153
Study 16083709 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 24 weeks (group B)
Number of subjects: 153
Study 16083709 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 24 weeks (group C)
Number of subjects: 153
Study 16083709 — intervention group
Group type: COMPARATOR
Intervention: HCV-3 patients with high viral load (>800,000 IU/mL)
Number of subjects: 153
Study 16083709 — intervention group
Group type: COMPARATOR
Intervention: HCV-3 patients with low viral load (≤800,000 IU/mL)
Number of subjects: 153
Study 12096200 — intervention group
Group type: EXPERIMENTAL
Intervention: nNO in PCD
Number of subjects: 157
Study 12096200 — intervention group
Group type: EXPERIMENTAL
Intervention: eNO in PCD
Number of subjects: 157
Study 12096200 — intervention group
Group type: EXPERIMENTAL
Intervention: nNO diagnostic use
Number of subjects: 157
Study 12096200 — intervention group
Group type: COMPARATOR
Intervention: nNO in Bx
Number of subjects: 157
Study 12096200 — intervention group
Group type: COMPARATOR
Intervention: nNO in CF
Number of subjects: 157
Study 12096200 — intervention group
Group type: COMPARATOR
Intervention: nNO in A
Number of subjects: 157
Study 12096200 — intervention group
Group type: COMPARATOR
Intervention: nNO in C
Number of subjects: 157
Study 12096200 — intervention group
Group type: COMPARATOR
Intervention: eNO in Bx
Number of subjects: 157
Study 12096200 — intervention group
Group type: COMPARATOR
Intervention: eNO in CF
Number of subjects: 157
Study 12096200 — intervention group
Group type: COMPARATOR
Intervention: eNO in A
Number of subjects: 157
Study 12096200 — intervention group
Group type: COMPARATOR
Intervention: eNO in C
Number of subjects: 157
Study 10601131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 to 40 mg/d)
Number of subjects: 30
Study 8543490 — intervention group
Group type: EXPERIMENTAL
Intervention: iv meropenem (1 g every 8 h)
Number of subjects: 237
Study 8543490 — intervention group
Group type: COMPARATOR
Intervention: iv ceftazidime (2 g every 8 h) plus iv amikacin (15 mg/kg/day in two or three divided doses)
Number of subjects: 237
Study 2024812 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg three times per day)
Number of subjects: 16
Study 2024812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29982294 — intervention group
Group type: COMPARATOR
Intervention: EX (aerobic training; treadmill 4 days/week for 30 minutes at 65%-70% of heart rate reserve)
Number of subjects: 180
Study 29982294 — intervention group
Group type: COMPARATOR
Intervention: EX + Mod-CR (aerobic training with moderate caloric restriction -250 kcal/d)
Number of subjects: 180
Study 29982294 — intervention group
Group type: COMPARATOR
Intervention: EX + High-CR (aerobic training with high caloric restriction -600 kcal/d)
Number of subjects: 180
Study 29523194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution umbilical cord cleansing regimen
Number of subjects: 30267
Study 29523194 — intervention group
Group type: COMPARATOR
Intervention: Previous child death in the family
Number of subjects: 30267
Study 29523194 — intervention group
Group type: COMPARATOR
Intervention: Overcrowding
Number of subjects: 30267
Study 29523194 — intervention group
Group type: COMPARATOR
Intervention: Home delivery
Number of subjects: 30267
Study 29523194 — intervention group
Group type: COMPARATOR
Intervention: Unclean cord care
Number of subjects: 30267
Study 29523194 — intervention group
Group type: COMPARATOR
Intervention: Multiple births
Number of subjects: 30267
Study 29523194 — intervention group
Group type: COMPARATOR
Intervention: Low birth weight
Number of subjects: 30267
Study 29523194 — intervention group
Group type: COMPARATOR
Intervention: Birth asphyxia
Number of subjects: 30267
Study 29523194 — intervention group
Group type: COMPARATOR
Intervention: Higher pregnancy order
Number of subjects: 30267
Study 25911347 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents Plus‐Parenting when Separated Programme
Number of subjects: 82
Study 25911347 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 82
Study 24692535 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPost) induced by ischemia to the arm
Number of subjects: 360
Study 24692535 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPost) induced by ischemia to the thigh
Number of subjects: 360
Study 24692535 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 mm Hg blood pressure cuff inflation)
Number of subjects: 360
Study 22564993 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 850 mg/twice per day
Number of subjects: 200
Study 22564993 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study 20417906 — intervention group
Group type: EXPERIMENTAL
Intervention: Charnley stem with Charnley cup
Number of subjects: 240
Study 20417906 — intervention group
Group type: EXPERIMENTAL
Intervention: Charnley stem with uncemented hemispherical cup (Duraloc)
Number of subjects: 240
Study 20417906 — intervention group
Group type: COMPARATOR
Intervention: Any revisions as endpoint
Number of subjects: 240
Study 20417906 — intervention group
Group type: EXPERIMENTAL
Intervention: Charnley stem
Number of subjects: 240
Study 17413694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine cessation
Number of subjects: 19
Study 16568708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with Der p 1 standardized allergens (total dose of 10,469 UBE)
Number of subjects: 60
Study 16568708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with Der p 1 standardized allergens
Number of subjects: 60
Study 16568708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12111069 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy (PC)
Number of subjects: 123
Study 12111069 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CO)
Number of subjects: 123
Study 10390703 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp seed tea (12 ounces)
Number of subjects: 22
Study 10390703 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp seed tea (24 ounces)
Number of subjects: 22
Study 10390703 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea (12 ounces)
Number of subjects: 22
Study 7760242 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 10.0 g/kg/d of dextrose and 4.0 g/kg/d of fat
Number of subjects: 14
Study 7760242 — intervention group
Group type: COMPARATOR
Intervention: Group B: 19.0 g/kg/d of dextrose and 0.5 g/kg/d of fat
Number of subjects: 14
Study 2269143 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints with large 'a' (radius of the maximal curvature of the sagittal anterior tooth curvature)
Number of subjects: 12
Study 2269143 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints with small 'a'
Number of subjects: 12
Study 6155987 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP/ABDV
Number of subjects: 84
Study 31996253 — intervention group
Group type: EXPERIMENTAL
Intervention: Good maternal growth monitoring knowledge
Number of subjects: 340
Study 31996253 — intervention group
Group type: COMPARATOR
Intervention: Poor maternal growth monitoring knowledge
Number of subjects: 340
Study 31801725 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 648
Study 31801725 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 648
Study 28993164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 200
Study 28993164 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 200
Study 26022762 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSC therapy
Number of subjects: 27
Study 26022762 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 24590053 — intervention group
Group type: COMPARATOR
Intervention: Blue light/placebo (BLU)
Number of subjects: 20
Study 24590053 — intervention group
Group type: EXPERIMENTAL
Intervention: White light/240‐mg caffeine (CAF)
Number of subjects: 20
Study 24590053 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light/240‐mg caffeine (BCAF)
Number of subjects: 20
Study 24590053 — intervention group
Group type: COMPARATOR
Intervention: White light/placebo (PLA)
Number of subjects: 20
Study 22594651 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes plus usual Quitline care (8 weeks of NRT patches and/or gum or lozenges, plus behavioural support)
Number of subjects: 1410
Study 22594651 — intervention group
Group type: COMPARATOR
Intervention: Usual Quitline care alone
Number of subjects: 1410
Study 18678424 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroposterior electrode position (Group B)
Number of subjects: 62
Study 18678424 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral electrode position (Group A)
Number of subjects: 62
Study 18678424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 16178829 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who received a letter about medical education (experimental group)
Number of subjects: 0
Study 16178829 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not receive a letter (control group)
Number of subjects: 0
Study 12850610 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg per day
Number of subjects: 171
Study 12850610 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg per day
Number of subjects: 171
Study 12850610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 10462244 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal A/C polysaccharide vaccine (MPS)
Number of subjects: 42
Study 10462244 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal A/C conjugate
Number of subjects: 42
Study 10462244 — intervention group
Group type: COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 42
Study 8857079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 12 mmol magnesium
Number of subjects: 0
Study 8857079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 24 mmol magnesium
Number of subjects: 0
Study 8857079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 4 mmol magnesium
Number of subjects: 0
Study 8857079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 8 mmol magnesium
Number of subjects: 0
Study 1676027 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate
Number of subjects: 1549
Study 1676027 — intervention group
Group type: COMPARATOR
Intervention: Control (suspected viral infections)
Number of subjects: 1549
Study 6809470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alucol
Number of subjects: 10
Study 6809470 — intervention group
Group type: EXPERIMENTAL
Intervention: Camalox
Number of subjects: 10
Study 31910279 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and zinc supplementation (5 mg of folic acid and 30 mg of elemental zinc daily for 6 months)
Number of subjects: 2370
Study 31910279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 6 months)
Number of subjects: 2370
Study 31910279 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and zinc supplementation
Number of subjects: 2370
Study 31910279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2370
Study 31291989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored insight visual support strategies
Number of subjects: 100
Study 31291989 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 100
Study 28679140 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU every 2 weeks for 12 weeks)
Number of subjects: 70
Study 28679140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25615911 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion condition (Cyberball paradigm)
Number of subjects: 299
Study 25615911 — intervention group
Group type: COMPARATOR
Intervention: Control condition (Cyberball paradigm)
Number of subjects: 299
Study 23837141 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir plus carnitine complex (GODEX®)
Number of subjects: 130
Study 23837141 — intervention group
Group type: COMPARATOR
Intervention: Entecavir monotherapy
Number of subjects: 130
Study 22084369 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of small-cell (SC) or lymphohistiocytic (LH) component
Number of subjects: 375
Study 22084369 — intervention group
Group type: EXPERIMENTAL
Intervention: Perivascular pattern
Number of subjects: 375
Study 22084369 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3 positivity
Number of subjects: 375
Study 22084369 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic subtyping concordance
Number of subjects: 375